ArticleThe Journal of biological chemistry2011
Isolation of a TRAIL antagonist from the serum of HIV-infected patients.
Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 17 citations in OpenAlex.
- TRAIL splice variant TRAILshort disrupts T cell receptor signaling and promotes immune tolerance in vivo.The Journal of clinical investigation · 2026Article
- NEUROCOGNITION, PLASMA LEVEL OF TUMOUR NECROSIS FACTORRELATED APOPTOSIS INDUCING LIGAND (TRAIL), AND PHAGOCYTIC ACTIVITY IN HIV PATIENTS ON LONG-TERM ANTIRETROVIRAL THERAPY.Annals of Ibadan postgraduate medicine · 2025Article
- The long road to TRAIL therapy: a TRAILshort detour.Oncotarget · 2021Article
- Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Identification of pathogenic TRAIL-expressing innate immune cells during HIV-1 infection in humanized mice by scRNA-Seq.JCI insight · 2020Article
- HIV elite control is associated with reduced TRAILshort expression.AIDS (London, England) · 2019Observational
- TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Translation to Practice: Accelerating the Cycle of Innovation to Impact.Mayo Clinic proceedings · 2019Review
- Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- The TRAIL: TRAILshort Axis in HIV Immunopathology.Critical reviews in immunology · 2018Review
- Retrospective Proteomic Analysis of Cellular Immune Responses and Protective Correlates of p24 Vaccination in an HIV Elite Controller Using Antibody Arrays.Microarrays (Basel, Switzerland) · 2016Article
- HMGB1 Is Involved in IFN-α Production and TRAIL Expression by HIV-1-Exposed Plasmacytoid Dendritic Cells: Impact of the Crosstalk with NK Cells.PLoS pathogens · 2016Article
- The macrophage: a therapeutic target in HIV-1 infection.Molecular and cellular therapies · 2014Review
- Anti-apoptotic mechanisms of HIV: lessons and novel approaches to curing HIV.Cellular and molecular life sciences : CMLS · 2013Review
- Altering cell death pathways as an approach to cure HIV infection.Cell death & disease · 2013Review
- EVER2 protein binds TRADD to promote TNF-α-induced apoptosis.Cell death & disease · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
Virus-host interactions are characterized by the selection of adaptive mechanisms by which to evade pathogenic and defense mechanisms, respectively. In primary T cells infected with HIV, HIV infection up-regulates TNF-related apoptosis inducing ligand (TRAIL) and death-inducing TRAIL receptors, but blockade of TRAIL:TRAIL receptor interaction does not alter HIV-induced cell death. Instead, HIV infection results in a novel splice variant that we call TRAIL-short (TRAIL-s), which antagonizes TRAIL-R2. In HIV patients, plasma TRAIL-s concentration increases with increasing viral load and renders cells resistant to TRAIL-induced death. Knockdown of TRAIL-s abrogates this resistance. We propose that TRAIL-s is a novel adaptive mechanism of apoptosis resistance acquired by HIV-infected cells to avoid their elimination by TRAIL-dependent effector mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.